I
Inhibikase Therapeutics, Inc. (IKT)
1.68
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
1.68
0.00 (0.00%)
Inhibikase Therapeutics, Inc. klinik bosqichdagi farmatsevtika kompaniyasi bo'lib, Parkinson kasalligi va unga bog'liq kasalliklar uchun terapevtik vositalarni ishlab chiqadi. Uning asosiy mahsulot nomzodi IkT-148009 bo'lib, u Abelson tirozin kinazining retseptorsiz inhibitori bo'lib, Parkinson kasalligi va oshqozon-ichak trakti davolash uchun 2a fazali klinik sinovlarda. Kompaniya, shuningdek, surunkali miyeloleykozning barqaror bosqichini davolash uchun saratonga qarshi vosita imatinib mesilatining prolegini IkT-001Pro-ni ishlab chiqmoqda. Inhibikase Therapeutics, Inc. Johns Hopkins universiteti, Arizona shtati universiteti va Michigan shtati universiteti bilan ilmiy-tadqiqot va ishlanmalar bo'yicha hamkorlik; va Sphaera Pharma Pte. Ltd. bilan hamkorlikdagi tadqiqot va ishlanmalar to'g'risidagi bitimga ega. Kompaniya 2008 yilda tashkil etilgan va Atlanta, Jorjiya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher H. Cabell FACC, M.D. | President, Head of Research & Development and Chief Medical Officer |
| Dr. John Adams Ph.D. | Chief Scientific Officer |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Development Operations |
| Mr. David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A. | Chief Financial Officer |
| Mr. Jeffrey J. Kagy | Chief Human Resources Officer |
| Mr. Mark T. Iwicki | CEO & Director |
| Mr. Timothy J. Pigot | Chief Commercial & Strategy Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-11-21 | 8-K | d65626d8k.htm |
| 2025-11-20 | 8-K | d20255d8k.htm |
| 2025-11-14 | 10-Q | ikt-20250930.htm |
| 2025-08-14 | 8-K | d946023d8k.htm |
| 2025-06-30 | 8-K | d109611d8k.htm |
| 2025-06-25 | CORRESP | filename1.htm |
| 2025-06-20 | S-3 | d77556ds3.htm |
| 2025-06-12 | DEFA14A | d947544ddefa14a.htm |
| 2025-05-14 | 10-Q | ikt-20250331.htm |
| 2025-05-12 | ARS | ikt-ars-2024.pdf |